Browse MUC1

Summary
SymbolMUC1
Namemucin 1, cell surface associated
Aliases CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ......
Chromosomal Location1q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Apical cell membrane Single-pass type I membrane protein Note=Exclusively located in the apical domain of the plasma membrane of highly polarized epithelial cells. After endocytosis, internalized and recycled to the cell membrane. Located to microvilli and to the tips of long filopodial protusions.; SUBCELLULAR LOCATION: Isoform 5: Secreted.; SUBCELLULAR LOCATION: Isoform Y: Secreted.; SUBCELLULAR LOCATION: Isoform 9: Secreted.; SUBCELLULAR LOCATION: Mucin-1 subunit beta: Cell membrane. Cytoplasm. Nucleus. Note=On EGF and PDGFRB stimulation, transported to the nucleus through interaction with CTNNB1, a process which is stimulated by phosphorylation. On HRG stimulation, colocalizes with JUP/gamma-catenin at the nucleus.
Domain PF01390 SEA domain
Function

The alpha subunit has cell adhesive properties. Can act both as an adhesion and an anti-adhesion protein. May provide a protective layer on epithelial cells against bacterial and enzyme attack.; FUNCTION: The beta subunit contains a C-terminal domain which is involved in cell signaling, through phosphorylations and protein-protein interactions. Modulates signaling in ERK, SRC and NF-kappa-B pathways. In activated T-cells, influences directly or indirectly the Ras/MAPK pathway. Promotes tumor progression. Regulates TP53-mediated transcription and determines cell fate in the genotoxic stress response. Binds, together with KLF4, the PE21 promoter element of TP53 and represses TP53 activity.

> Gene Ontology
 
Biological Process GO:0000075 cell cycle checkpoint
GO:0000077 DNA damage checkpoint
GO:0000082 G1/S transition of mitotic cell cycle
GO:0006473 protein acetylation
GO:0006475 internal protein amino acid acetylation
GO:0006486 protein glycosylation
GO:0006493 protein O-linked glycosylation
GO:0006977 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest
GO:0006978 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator
GO:0007050 cell cycle arrest
GO:0007093 mitotic cell cycle checkpoint
GO:0007162 negative regulation of cell adhesion
GO:0007346 regulation of mitotic cell cycle
GO:0008630 intrinsic apoptotic signaling pathway in response to DNA damage
GO:0009100 glycoprotein metabolic process
GO:0009101 glycoprotein biosynthetic process
GO:0010944 negative regulation of transcription by competitive promoter binding
GO:0010948 negative regulation of cell cycle process
GO:0016266 O-glycan processing
GO:0016570 histone modification
GO:0016573 histone acetylation
GO:0018205 peptidyl-lysine modification
GO:0018393 internal peptidyl-lysine acetylation
GO:0018394 peptidyl-lysine acetylation
GO:0030330 DNA damage response, signal transduction by p53 class mediator
GO:0031056 regulation of histone modification
GO:0031058 positive regulation of histone modification
GO:0031570 DNA integrity checkpoint
GO:0031571 mitotic G1 DNA damage checkpoint
GO:0033627 cell adhesion mediated by integrin
GO:0033628 regulation of cell adhesion mediated by integrin
GO:0033629 negative regulation of cell adhesion mediated by integrin
GO:0035065 regulation of histone acetylation
GO:0035066 positive regulation of histone acetylation
GO:0036003 positive regulation of transcription from RNA polymerase II promoter in response to stress
GO:0042770 signal transduction in response to DNA damage
GO:0042771 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator
GO:0042772 DNA damage response, signal transduction resulting in transcription
GO:0043413 macromolecule glycosylation
GO:0043543 protein acylation
GO:0043618 regulation of transcription from RNA polymerase II promoter in response to stress
GO:0043620 regulation of DNA-templated transcription in response to stress
GO:0043967 histone H4 acetylation
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044773 mitotic DNA damage checkpoint
GO:0044774 mitotic DNA integrity checkpoint
GO:0044783 G1 DNA damage checkpoint
GO:0044819 mitotic G1/S transition checkpoint
GO:0044843 cell cycle G1/S phase transition
GO:0045786 negative regulation of cell cycle
GO:0045787 positive regulation of cell cycle
GO:0045930 negative regulation of mitotic cell cycle
GO:0070085 glycosylation
GO:0071156 regulation of cell cycle arrest
GO:0071158 positive regulation of cell cycle arrest
GO:0072331 signal transduction by p53 class mediator
GO:0072332 intrinsic apoptotic signaling pathway by p53 class mediator
GO:0072395 signal transduction involved in cell cycle checkpoint
GO:0072401 signal transduction involved in DNA integrity checkpoint
GO:0072413 signal transduction involved in mitotic cell cycle checkpoint
GO:0072422 signal transduction involved in DNA damage checkpoint
GO:0072431 signal transduction involved in mitotic G1 DNA damage checkpoint
GO:0090068 positive regulation of cell cycle process
GO:0090239 regulation of histone H4 acetylation
GO:0090240 positive regulation of histone H4 acetylation
GO:0097193 intrinsic apoptotic signaling pathway
GO:1901796 regulation of signal transduction by p53 class mediator
GO:1901797 negative regulation of signal transduction by p53 class mediator
GO:1901983 regulation of protein acetylation
GO:1901985 positive regulation of protein acetylation
GO:1901987 regulation of cell cycle phase transition
GO:1901988 negative regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1901991 negative regulation of mitotic cell cycle phase transition
GO:1902165 regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator
GO:1902166 negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator
GO:1902229 regulation of intrinsic apoptotic signaling pathway in response to DNA damage
GO:1902230 negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage
GO:1902253 regulation of intrinsic apoptotic signaling pathway by p53 class mediator
GO:1902254 negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator
GO:1902275 regulation of chromatin organization
GO:1902400 intracellular signal transduction involved in G1 DNA damage checkpoint
GO:1902402 signal transduction involved in mitotic DNA damage checkpoint
GO:1902403 signal transduction involved in mitotic DNA integrity checkpoint
GO:1902532 negative regulation of intracellular signal transduction
GO:1902806 regulation of cell cycle G1/S phase transition
GO:1902807 negative regulation of cell cycle G1/S phase transition
GO:1905269 positive regulation of chromatin organization
GO:2000045 regulation of G1/S transition of mitotic cell cycle
GO:2000134 negative regulation of G1/S transition of mitotic cell cycle
GO:2000756 regulation of peptidyl-lysine acetylation
GO:2000758 positive regulation of peptidyl-lysine acetylation
GO:2001020 regulation of response to DNA damage stimulus
GO:2001021 negative regulation of response to DNA damage stimulus
GO:2001233 regulation of apoptotic signaling pathway
GO:2001234 negative regulation of apoptotic signaling pathway
GO:2001242 regulation of intrinsic apoptotic signaling pathway
GO:2001243 negative regulation of intrinsic apoptotic signaling pathway
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001159 core promoter proximal region DNA binding
GO:0002039 p53 binding
Cellular Component GO:0000785 chromatin
GO:0000790 nuclear chromatin
GO:0005796 Golgi lumen
GO:0016324 apical plasma membrane
GO:0044454 nuclear chromosome part
GO:0045177 apical part of cell
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-5621481: C-type lectin receptors (CLRs)
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-5621480: Dectin-2 family
R-HSA-5083632: Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS)
R-HSA-5083636: Defective GALNT12 causes colorectal cancer 1 (CRCS1)
R-HSA-5083625: Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC)
R-HSA-1643685: Disease
R-HSA-3906995: Diseases associated with O-glycosylation of proteins
R-HSA-3781865: Diseases of glycosylation
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-392499: Metabolism of proteins
R-HSA-5173105: O-linked glycosylation
R-HSA-913709: O-linked glycosylation of mucins
R-HSA-597592: Post-translational protein modification
R-HSA-449147: Signaling by Interleukins
R-HSA-977068: Termination of O-glycan biosynthesis
Summary
SymbolMUC1
Namemucin 1, cell surface associated
Aliases CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ......
Chromosomal Location1q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MUC1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between MUC1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28126925Acute Myeloid LeukemiaInhibit immunity (T cell function)MUC1 induces increased expression of c-myc in EVs that induces proliferation in the target MDSC population via downstream effects on cell cycle proteins.
27604597Prostate carcinomaPromote immunity (T cell function); essential for immunotherapyIn conclusion, vaccination with Tn-MUC1-loaded DCs in nmCRPC patients appears to be safe, able to induce significant T-cell responses, and have biological activity as measured by the increase in PSADT following vaccination.
29258739Triple-Negative Breast CancerPromote immunity (T cell function); essential for immunotherapyCombination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer. In vivo studies demonstrated that the NP-based mRNA vaccine, targeted to mannose receptors on DCs, could successfully express tumor antigen in the DCs of the lymph node; that the NP vaccine could induce a strong, antigen-specific, in vivo cytotoxic T lymphocyte response against TNBC 4T1 cells; and that combination immunotherapy of the vaccine and anti-CTLA-4 monoclonal antibody could significantly enhance anti-tumor immune response compared to the vaccine or monoclonal antibody alone.
24605110Pancreatic CarcinomaInhibit immunity; immunotherapy targetPancreatic Cancer Cells Isolated from Muc1-Null Tumors Favor the Generation of a Mature Less Suppressive MDSC Population. This is the first report that clearly suggests a functional role of pancreatic tumor-associated MUC1 in the development of functional MDSCs.
29263152Triple-negative breast carcinomaInhibit immunity (T cell function)The immune checkpoint ligand PD-L1 and the transmembrane mucin MUC1 are upregulated in triple-negative breast cancer (TNBC), where they contribute to its aggressive pathogenesis. Here, we report that genetic or pharmacological targeting of the oncogenic MUC1 subunit MUC1-C is sufficient to suppress PD-L1 expression in TNBC cells. Mechanistic investigations showed that MUC1-C acted to elevate PD-L1 transcription by recruitment of MYC and NF-κB p65 to the PD-L1 promoter. In an immunocompetent model of TNBC in which Eo771/MUC1-C cells were engrafted into MUC1 transgenic mice, we showed that targeting MUC1-C associated with PD-L1 suppression, increases in tumor-infiltrating CD8+ T cells and tumor cell killing. MUC1 expression in TNBCs also correlated inversely with CD8, CD69, and GZMB, and downregulation of these markers associated with decreased survival.
16467101AdenocarcinomaPromote immunity (T cell function); essential for immunotherapyMannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Immunization produced T-cell responses in all patients with evidence of tumor stabilization in 2 of the 10 advanced cancer patients treated.
28288138Non-Small Cell Lung CarcinomaInhibit immunityThe present studies demonstrate that MUC1-C activates PD-L1 expression in NSCLC cells. We show that MUC1-C increases NF-κB p65 occupancy on the CD274/PD-L1 promoter and thereby drives CD274 transcription. In concert with these results, targeting MUC1-C in NSCLC tumors suppresses PD-L1 and induces these effectors of innate and adaptive immunity. These findings support a previously unrecognized central role for MUC1-C in integrating PD-L1 activation with suppression of immune effectors and poor clinical outcome.
19196663LymphomaInhibit immunityIn addition to diminishing recruitment of MDSCs, the effect of MUC1/sec on MDSC-suppressive mechanisms was investigated. MUC1/sec, or its unique immunoenhancing peptide, is capable of blocking expression of arginase 1 and production of reactive oxygen species in MDSCs, implicated in the suppression of T cells.
24894093lung carcinomaInhibit immunityThe goals of the present study were to define the effects of simultaneous cisplatin/tecemotide therapy on tumor development in a human mucin 1 (MUC1) transgenic lung cancer mouse model and to examine the effects of radiotherapy (RTX) on splenocytes, serum cytokines, and immune response to tecemotide.
29633523carcinomaPromote immunitySynthetic vaccines based on MUC1 tandem repeat motifs, comprising tumor-associated 2,3-sialyl-T antigen, conjugated to the immunostimulating tetanus toxoid, are reported herein.
21540305Pleural Malignant MesotheliomaInhibit immunity (T/NK cell function); immunotherapy targetMucin (MUC)1, which is expressed and recognised by cytotoxic T-cells in numerous cancer types, has not been investigated as a potential immune target in MPM. Thus, MUC1 expression and antigen presentation by MPM cells may represent an attractive target for immunotherapeutic treatment of MPM despite its hyperglycosylated profile.
18661524Ovarian CancinomaImmunotherapy targetImmunotherapy against MUC1 could be effective in the treatment of epithelial ovarian cancer.
18561323Bladder CarcinomaImmunotherapy targetUpregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection.
22964632Ovarian CarcinomaInhibit immunity; Candidate for immunotherapy targetMucin 1 (MUC1) glycoprotein is a tumor-associated antigen overexpressed in ovarian cancer cells, making it a potential target for immune therapy. Compared with the KrasPten mice with tumors, the MUC1KrasPten mice show increased loco-regional metastasis and augmented accumulation of CD4+Foxp3+ immune-suppressive regulatory T cells. Vaccination of MUC1KrasPten mice with type 1 polarized dendritic cells (DC1) loaded with a MUC1 peptide (DC1-MUC1) can circumvent tumor-mediated immune suppression in the host, activate multiple immune effector genes and effectively prolong survival.
18713982Pancreatic AdenocarcinomaInhibit immunityMUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. MUC1, a membrane tethered mucin glycoprotein, is overexpressed and aberrantly glycosylated in >80% of human ductal pancreatic adenocarcinoma. Data shows that during pancreatic cancer progression, MUC1-mediated mechanisms enhance the onset and progression of the disease, which in turn regulate the immune responses.
17671159Non-Small Cell Lung CarcinomaImmunotherapy targetL-BLP25 is a peptide vaccine strategy that targets the exposed core peptide of MUC1. In preclinical studies, L-BLP25 induced a cellular immune response characterized by T-cell proliferation in response to MUC1 and production of IFN-gamma.
25168392renal cell carcinomaPromote immunity (T cell infiltration)This was associated with an early detectable cellular immunity to MUC1 and comparatively more infiltration by CD8? T cells. CD8? T-cell infiltration was observed in various organs, including the kidneys, irrespective of the presence of tumor or the expression of MUC1 by MVA.
Summary
SymbolMUC1
Namemucin 1, cell surface associated
Aliases CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ......
Chromosomal Location1q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MUC1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.54 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolMUC1
Namemucin 1, cell surface associated
Aliases CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ......
Chromosomal Location1q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MUC1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.6280.214
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.810.092
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2280.812
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9161.3970.0845
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.3190.639
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.5030.689
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2390.667
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.950.275
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.5790.542
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.3150.528
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8320.795
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.5410.0369
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MUC1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.407.40.0709
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.407.40.096
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)2117017.6-17.60.0806
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)1311018.2-18.20.199
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMUC1
Namemucin 1, cell surface associated
Aliases CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ......
Chromosomal Location1q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MUC1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMUC1
Namemucin 1, cell surface associated
Aliases CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ......
Chromosomal Location1q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MUC1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MUC1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMUC1
Namemucin 1, cell surface associated
Aliases CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ......
Chromosomal Location1q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MUC1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMUC1
Namemucin 1, cell surface associated
Aliases CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ......
Chromosomal Location1q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MUC1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMUC1
Namemucin 1, cell surface associated
Aliases CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ......
Chromosomal Location1q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MUC1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMUC1
Namemucin 1, cell surface associated
Aliases CD227; PEM; ADMCKD; ADMCKD1; MCKD; MCKD1; mucin 1, transmembrane; medullary cystic kidney disease 1 (autosom ......
Chromosomal Location1q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MUC1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.